IL6 and COVID-19: Moreover, COVID-19 patients experience major lung damage (due to viral replication) and immune dysregulation, which is modulated by the use of corticosteroids, anti–IL-6 monoclonal antibodies (tocilizumab, sarilumab), or other immunomodulatory agents [15].